氟尿嘧啶植入剂的研究进展及其在腺癌中的临床应用

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (7): 827-831.

氟尿嘧啶植入剂的研究进展及其在腺癌中的临床应用

昝培霞¹, 颜士杰²

¹安徽医科大学临床医学七年制, ²安徽医科大学第一附属医院妇产科,合肥 230022,安徽

收稿日期:2010-03-11 修回日期:2010-04-24 出版日期:2010-07-26 发布日期:2020-09-15
通讯作者: 颜士杰,女,主任医师,副教授,研究生导师,主要从事妇科肿瘤研究。Tel: 13855140535 E-mail: ysj5851@126.com
作者简介:昝培霞,女,硕士研究生,主要从事妇科肿瘤研究。Tel: 13966710359 E-mail: zanpeixia823@163.com

Advances in study of fluorouracil for implantation and its clinical application in adenocarcinoma

ZAN Pei-xia¹, YAN Shi-jie²

¹Clinical Medical Student of 7-year Program of Anhui Medical University, ²Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University,Hefei 230022,Anhui,China

Received:2010-03-11 Revised:2010-04-24 Online:2010-07-26 Published:2020-09-15

摘要/Abstract

摘要： 氟尿嘧啶植入剂是一种新型的植入用缓释氟尿嘧啶制剂,是国家食品药品监督管理局批准的第一个抗肿瘤控释植入剂。氟尿嘧啶植入剂的主要有效成分为5-氟尿嘧啶。氟尿嘧啶植入剂可提高局部药物浓度,延长有效药物浓度时间,降低全身毒副反用。本文综述了氟尿嘧啶植入剂的药代动力学、药理作用及在腺癌中的临床应用。

关键词: 氟尿嘧啶植入剂, 腺癌, 临床应用

Abstract: Fluorouracil for implantation is a new implanting sustained release preparation, and it is the first tumor therapy controlled release implantation that has been ratified by SFDA.5-fluorouracil is the main component of fluorouracil for implantation. Fluorouracil for implantation can elevate the local drug concentration,extend the time of effective drug concentration,reduce the general toxic and side-effect. The article contains fluorouracil for implantation pharmacokinetics, pharmacologic and apply to adenocarcinoma.

Key words: Fluorouracil for implantation, Adenocarcinoma., Clinical application

中图分类号:

R969

昝培霞, 颜士杰. 氟尿嘧啶植入剂的研究进展及其在腺癌中的临床应用[J]. 中国临床药理学与治疗学, 2010, 15(7): 827-831.

ZAN Pei-xia, YAN Shi-jie. Advances in study of fluorouracil for implantation and its clinical application in adenocarcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 827-831.

参考文献

[1] Jung M,Berger G,Pohlen U,et al.Simultaneous determination of 5-fluorouracil and its active metabolites in serum and tissue by high-performance liquid chromatography[J].J Chromatogr B Biomed Sci Appl,1997,702(1/2):193-202.
[2] 刘华顶,王世亮,武四化,等.缓释氟尿嘧啶植入剂在大肠癌患者的药动学研究[J].中国新药杂志,2005,14(10):1199-1201.
[3] 汤钊.现代肿瘤学[M].上海:上海医科大学出版社,1993:545-547.
[4] Gunduz N,Fisher B,Saffer EA.Effect of surgical removal on the growth and kinetics of residual tumor[J].Cancer Res,1979,39(10):3861-3865.
[5] Qadri SS,Wang JH,Coffey JC,et al.Can surgery for cancer accelerate the progression of secondary tumors within residual minimal disease at both local and systemic levels?[J].Ann Thorac Surg,2005,80(3):1046-1050.
[6] Fisher B, Gunduz N, Saffer EA.Influence of the interva between primary tumor removal and themotherapy in kinetics and growth of metastases[J].Cancer Res,1983,43(4):1488-1492.
[7] Sethna KS,Sugarbaker PH.New prospects for the control of peritonealsurface dissemination of gastric cancer using perioperative in traperitoneal chemotherapy[J].Cancer Therapy,2004,2(A):79-84.
[8] Nicoll AJ,Colledge DL,Toole JJ,et al.Inhibition of duck hepatitisB virus replication by 92(22phosphonylmethoxyethyl)adenine,an acyclic phosphonate nucleoside analogue[J].Antimicrobial Agents Chemother,1998,42(12):3130-3135.
[9] 刘华顶,王世亮,武四化,等.术中植入缓释氟尿嘧啶治疗大肠癌临床研究[J].腹部外科杂志,2005,1(83):175-176.
[10] 储成顶,成微,王世亮,等.缓释植入剂局部给药治疗系统的药动学模型[J].中国新药杂志,2004,13(7):613-616.
[11] Sipos EP,Tyler B,Piantadosi S,et al.Optimizing interstitialdelivery of BCNU from controlled release polymers for the treatmentof brain tumors[J].Cancer Chemother Pharmacol,1997,39(5):383.
[12] 陈开运,向国安,王汉宁,等.射频消融及^125I粒子植入在预防肝癌切除术后局部复发的作用[J].中华肿瘤杂志,2007,29(8):626-628.
[13] 赵卫东,凌斌,祝怀平,等.卵巢恶性肿瘤免疫逃逸与转录因子T-bet、GATA3相关性的研究[J].安徽医科大学学报,2004,39(3):198-200.
[14] 林海晨,仵明宪.乳腺癌术中应用5-FU缓释剂近期疗效观察[J].山东医药,2008,48(43):47-48.
[15] 胡明,雷建,陈远光,等.老年胃肠恶性肿瘤术中腹腔植入缓释氟尿嘧啶的临床观察[J].中国老年学杂志,2008,28(18):1827-1828.
[16] 谢斌,吴刚,唐春,等.肝癌切除术后残肝断面5-FU缓释剂植入对肝癌肝内转移复发的影响[J].肝胆外科杂志,2007,15(6):421-423.
[17] Blanco E,Weinberg BD,Stowe NT,et al.Local release of dexamethasonefrom polymer millirods effectively prevents fibrosis after radiofrequency ablation[J].J Biomed Mater Res A,2006,76(1):174-182.
[18] Westphal M,Hilt DC,Bprtey E,et al.A phase 3 trial of locachemotherapy with biodegradable carmustine (BCNU) wafers(Gliadelwafers)in patients with primary malignant glioma[J]. Neuro Oncol, 2003,5(2):79-88.
[19] Goldberg EP,Hadba AR,Almond BA,et al.Intratumoral cancer chemotherapy and immunotherapy:opportunities for nonsystemic preoperative drug delivery[J].J Pharm Pharmacol,2002,54(2):159-180.
[20] Janunger KG,Hafstrom L,Nygren P,et al.A systematic overview of chemotherapy effects in gastric cancer[J].Acta Oncol,2001,40(2/3):309.
[21] 袁绍纪,李际文,吕学明.手术切除联合局部植入5-FU多聚缓释体化疗治疗颅内恶性肿瘤[J].中华神经外科疾病研究杂志,2006,5(2):163-164.
[22] 卫东,袁祖荣,倪泉兴,等.5-FU缓释剂瘤内植入治疗胰腺癌的实验研究和临床[J].China Medical Abstracts(Surgery),2005,14(2):148-154.
[23] 陈铮铮,凌斌,赵卫东,等.5-Fu缓释剂局部埋植治疗卵巢癌腹膜后转移的实验研究[J].安徽医科大学学报,2005,40(6):538-540.